Gadolinium-based MRI contrast carries a risk in patients with chronic kidney disease. What is this concern generally associated with?

• A. Allergic reaction to contrast.
• B. Increased radiation exposure.
• C. No risk.
• D. Gadolinium-based contrast carries risk in CKD.

Answer: (D)

Gadolinium-based contrast can cause a specific, CKD-related risk: nephrogenic systemic fibrosis. When kidney function is impaired, gadolinium may linger and trigger this rare but serious fibrosing disorder, affecting skin, joints, and internal organs. The risk is higher with more unstable, linear gadolinium formulations and with more severe kidney dysfunction, so clinicians often avoid gadolinium in advanced CKD or choose safer agents and the lowest effective dose, or seek non-contrast imaging when possible. The other options aren’t the main CKD-specific concern—allergic reactions can occur but aren’t tied to kidney function, and MRI doesn’t involve ionizing radiation. Therefore, acknowledging that gadolinium-based contrast carries risk in CKD reflects the NSF concern.